Herskowitz Neil 4

What Happened
Neil Herskowitz, a director of Journey Medical Corp (DERM), was granted 50,000 restricted stock units (RSUs) on July 1, 2026. The Form 4 reports an acquisition (code A) of 50,000 shares at $0.00 (no cash paid at grant). The RSUs vest in three installments: 16,666 shares on July 1, 2029; 16,667 shares on July 1, 2030; and 16,667 shares on July 1, 2031.

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 2, 2026 (timely filing).
• Amount: 50,000 RSUs; reported acquisition price $0.00.
• Vesting schedule: 16,666 (7/1/2029), 16,667 (7/1/2030), 16,667 (7/1/2031) (see footnote F1).
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F1 describes the specific vesting schedule above; F2 notes these are RSUs that vest over time.
• Transaction code: A = Award/Grant (compensation), not an open-market buy or sale.

Context
RSUs are compensation awards that convert into shares only as they vest — they are not immediate purchases or sales. A grant reported at $0 means no cash was paid by the insider at grant; the economic value to the insider will depend on Journey Medical’s share price at each vesting date. Director RSU grants are common as part of routine compensation and do not by themselves indicate buying or selling sentiment.